Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Biochemical and Biophysical Research Communications 158 (1989), S. 244-250 
    ISSN: 0006-291X
    Keywords: [abr] MOPS; 3-[N-Morpholino]propanesulfonic acid ; [abr] PAM; Peptidyl-Glycine α-Amidating Monooxygenase ; [abr] SSC; Sodium-Sodium Citrate ; [abr] TRH; Thyrotropin-Releasing Hormone
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology , Physics
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Biochemical and Biophysical Research Communications 158 (1989), S. 244-250 
    ISSN: 0006-291X
    Keywords: [abr] MOPS; 3-[N-Morpholino]propanesulfonic acid ; [abr] PAM; Peptidyl-Glycine α-Amidating Monooxygenase ; [abr] SSC; Sodium-Sodium Citrate ; [abr] TRH; Thyrotropin-Releasing Hormone
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology , Physics
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1420-908X
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The effects of zinc gluconate have been studied on rat peritoneal mast cells and rat basophilic leukemia cells (RBL 2H3) stimulated by various secretagogues. The IC50's of zinc gluconate on peritoneal cells were (μM)∶1.6, 1.9, 5.4 and 18 for ionophore A23187, phorbol 12-myristate 13-acetate, substance P and immunoglobulin E-antigen, respectively. Higher concentrations of zinc gluconate were required to inhibit histamine secretion from RBL 2H3 cells, i.e. 12 μM (ionophore A23187) and 140 μM (immunoglobulin E-antigen). Zinc gluconate (10−4 to 10−3 M) also inhibited the IgE-dependent contraction of guinea pig trachea but was unable to affect that induced by exogenous histamine. These results suggest that zinc gluconate acts intracellularly and is selective of “typical” or “connective tissue” mast cells.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1420-908X
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The role of the sodium pump in the plasma membrane potential changes induced by compound 48/80 and by antigenic challenge has been investigated using a fluorescent potential sensitive probe,bis-oxonol. Compound 48/80 induced a fast decrease of the fluorescence ofbis-oxonol followed by a delayed decrease. The antigenic stimulation induced only a delayed decrease of fluorescence. Zinc gluconate inhibited the first decrease but did not alter the second one. The delayed decrease was inhibited by ouabain or by the absence of potassium. These results suggest that compound 48/80 induced mast cell secretion via a zinc-sensitive mechanism followed by activation of the sodium pump. The changes in the plasma membrane potential during the antigenic stimulation are due to the activation of the sodium pump but occur after the secretion process.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    Health economics in prevention and care 0 (2000), S. 20-23 
    ISSN: 1439-6637
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: 1999 was marked in France by the publication of numerous texts of laws and decrees specifying the method for fixing the prices of reimbursable drugs in France. While the situation regarding non-reimbursable drugs is fairly similar to that of other consumer goods, the French administration keeps reimbursable drugs within a controlled price system in an attempt to contain the cost of their reimbursement by Social Security. In this article we will analyse the framework of laws and regulations behind the pricing system in France as well as the way in which prices are fixed by the Economic Committee for Health Products following the opinion of the Transparency Commission on the reimbursable nature of those medicines. Quite apart from these two topics, it is interesting to analyse the increasingly important role of the new structures regulating the prices of those drugs. Opinions are, to say the least, divided as to whether such a complex system, when viewed from the outside, meets the objective set by the French Administration and whether a trend towards more European pricing structures is now emerging.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Electronic Resource
    Electronic Resource
    Springer
    Health economics in prevention and care 0 (2000), S. 24-27 
    ISSN: 1439-6637
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: L'année 1999 a été marquée en France par la publication de nombreux textes de lois et décrets précisant le mode de fixation des prix des médicaments remboursables en France. Si la situation des médicaments non remboursables est assez proche de celle des autres biens de consommation, l'Administration Française maintient les médicaments remboursables dans un système de prix administrés afin de tenter de contenir, le coût de leur prise en charge par la Sécurité Sociale. Nous analysons dans cet article le cadre légal et réglementaire du système de fixation des prix en France ainsi que le mode de fixation de ces prix par le Comité Economique des Produits de Santé après Avis de la Commission de Transparence sur le caractère remboursable de ces médicaments. En dehors de ces deux instances, il est intéressant d'analyser le rôle grandissant des nouvelles structures de régulation des prix de ces mêmes médicaments. Un tel système très complexe, vu de l'extérieur atteint-il l'objectif fixé par l'Administration Française et une évolution vers des structures de fixation de prix plus européennes se dessine-t-elle? Les avis sont pour le moins partagés.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...